Aberrant activation of the Ras/Raf/MAPK/ERK kinase/extracellular signal-regulated kinase cascade and the VEGF pathway are commonly observed in breast cancer cells leading to malignant cell ...

Fintel reports that on January 7, 2025, B of A Securities upgraded their outlook for Erasca (NasdaqGS:ERAS) from Neutral to ...

Verastem, Inc. is on the verge of FDA approval for their combo therapy avutometinib-defactinib, targeting low-grade serous ...

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, ...

When compared to the broader market, Verastem Oncology has shown exceptional performance. The company’s stock has surged 30.57% year-to-date, a stark contrast to the S&P 500’s meager performance of -0 ...

(Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today ...

"We continue to make progress across our pipeline to develop novel therapies alone or in synergistic combinations that have the potential to improve outcomes in RAS/MAPK pathway-driven cancers.